Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approval Is "First Action" For 32% Of NMEs; Rate Less Than Other NDAs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA approved approximately one-third of new molecular entities with user fee deadlines in 2002 on the first cycle.

You may also be interested in...



Average Approval Time Is Slower For Drugs, Faster For Biologics

Average time to approval rose in 2004 to 18.7 months for NMEs, but biologics average was significantly lower at 20.2 months. 2003 averages were 17.1 for drugs, 36.9 for biologics

Average Approval Time Is Slower For Drugs, Faster For Biologics

Average time to approval rose in 2004 to 18.7 months for NMEs, but biologics average was significantly lower at 20.2 months. 2003 averages were 17.1 for drugs, 36.9 for biologics

FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003

FDA’s efforts to increase first-cycle approvals appear to be paying off, with the agency showing a significant improvement in 2003 compared to 2002.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel